Within their Nature Medicine statement.

Advance in K-Ras-mutated cancers research A team of cancer researchers from several Boston academic medical centers has discovered a potential treatment for several tumors which have resisted previous targeted therapy approaches. Within their Nature Medicine statement, which is receiving early online release, investigators from Dana-Farber Cancers Institute , Massachusetts General Hospital Cancer Center, and Beth Israel Deaconess Medical Center Cancer Center statement that combining two different kinase inhibitors – medications that hinder specific cell-growth pathways – resulted in significant tumor shrinkage in mice with lung cancer powered by mutations in the K-Ras gene.Equivalent trials of lenalidomide maintenance possess verified this risk.19,20 Second main cancers are section of the natural history of myeloma and its treatment.21 Inside our study, there have been seven instances of acute lymphoblastic leukemia or Hodgkin’s disease among patients who had received induction therapy with dexamethasone, cyclophosphamide, etoposide, and cisplatin or had undergone two transplantations and had received lenalidomide maintenance therapy for at least 2 years. An increased risk of severe lymphoblastic leukemia or Hodgkin’s disease hasn’t previously been reported among individuals with myeloma.21 Currently, the beneficial effect of lenalidomide maintenance therapy on event-free survival suggests that more individuals receive benefit than are harmed; however, the chance of second primary cancers is serious, and follow-up periods will end up being necessary to accurately quantify the risk longer.